Page 39 - Shimadzu Journal vol.9 Issue2

Latest topics 4

Release of the Nexera XS inert

High-Performance Liquid Chromatograph

Shimadzu Corporation announces the release of the Nexera XS of Pharmaceutical Sciences, Kyoto University, was designed and
inert high-performance liquid chromatograph globally. The Nexera developed in order to resolve such problems. Nonmetallic mate-
XS inert incorporates rust-resistant materials and nonmetallic rials are used for the flow lines through which the samples pass,
materials that limit the adsorption of molecules to provide stable preventing adsorption of molecules prone to metallic adsorption
measurements of biopharmaceuticals and medium molecule phar- by the instrument. As a result, sensitivity in LC and LC/MS tests is
1
maceuticals* . Through this product, Shimadzu aims to expand its not prone to decrease, and the accuracy of data is maintained even
business performance in the market for biopharmaceuticals such in repeated analyses. Additionally, rust-resistant materials are used
as antibody drugs and medium molecule pharmaceuticals such as in the design, so that the instrument provides stable operation and
nucleic acid drugs. highly reliable data, even after long-term use of saline and other
In recent years, in the pharmaceutical industry, the development solutions for corrosive to metals.
of biopharmaceuticals, such as antibody drugs, as well as medium As an LC manufacturer, Shimadzu has the top share of the
molecule pharmaceuticals utilizing peptides and oligonucleotides Japanese market, and our flagship Nexera series LC system is used
has accelerated. These new modalities* have chemical characteris- by a wide range of customers thanks to its high basic performance
2
tics that differ from low molecular compounds, which are currently level and excellent usability. The Nexera XS inert is intended
the mainstream in pharmaceuticals. Accordingly, new techniques to expand our global share by strengthening our share of the
will be required in situations such as research and development pharma/biopharma market. By continuing to heighten data reli-
related to drug efficacy and toxicity as well as in manufacturing ability, Shimadzu is promoting more streamlined analysis and
and quality control. High-performance liquid chromatographs testing, thereby contributing to the rapid development of bio- and
(LC) and liquid chromatograph mass spectrometers (LC-MS) may medium molecule pharmaceuticals.
also pose problems. For example, molecules prone to adsorption *1 Medium molecule pharmaceuticals: Pharmaceuticals that use molecules with a molecular
by metals become adsorbed within the instrument during analysis, weight between 500 and 2000
*2 Modality: The type and form of pharmaceuticals
leading to data inaccuracies and reducing sensitivity. In addition,
depending on the test method, the LC system might rust, and per-
formance might deteriorate because of long-term use or insufficient
cleaning after use. For more details, visit Nexera XS inert
Nexera XS inert, based on the outcome of cooperative re-
search with Professor Yasushi Ishihama of the Graduate School

Shimadzu Journal vol.9 Issue2 72